News >

FDA Approves Pemetrexed Injection for Nonsquamous NSCLC and Malignant Pleural Mesothelioma

Gina Columbus @ginacolumbusonc
Published: Monday, Feb 10, 2020

The FDA has granted a final approval to pemetrexed for injection (Pemfexy), an alternative to standard pemetrexed (Alimta) for the treatment of patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) and for those with malignant pleural mesothelioma.

“This agreement provides for a release of all claims by the parties and allows for an initial entry of Pemfexy into the market, equivalent to approximately a three-week supply of current Alimta utilization, on February 1, 2022, and a subsequent uncapped entry on April 1, 2022,” Eagle Pharmaceuticals stated in the press release.
Eagle Pharmaceuticals receives final FDA approval for Pemfexy (pemetrexed for injection) [news release]: Woodcliff Lake, NJ. Eagle Pharmaceuticals. Published February 10, 2020. Accessed February 10, 2020.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication